DOP2010000189A - Vacunas contra la malaria - Google Patents

Vacunas contra la malaria

Info

Publication number
DOP2010000189A
DOP2010000189A DO2010000189A DO2010000189A DOP2010000189A DO P2010000189 A DOP2010000189 A DO P2010000189A DO 2010000189 A DO2010000189 A DO 2010000189A DO 2010000189 A DO2010000189 A DO 2010000189A DO P2010000189 A DOP2010000189 A DO P2010000189A
Authority
DO
Dominican Republic
Prior art keywords
antigen
component
rts
unbound
immunogenic particle
Prior art date
Application number
DO2010000189A
Other languages
English (en)
Inventor
Dominique Ingrid Lemoine
Florence Emilie Jeanne Francoise Wauters
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40584700&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2010000189(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of DOP2010000189A publication Critical patent/DOP2010000189A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un componente para una vacuna contra la malaria que comprende: a) una partícula inmunógena RTS,S ylo b) una partícula inmunógena que se deriva de la proteína CS de una o más cepas de P. vivax y el antígeno S de Ia Hepatitis B y opcionalmente el antígeno S sin fusionar, o c) una partícula inmunógena que comprende RTS, CSV-S y opcionalmente el antígeno S sin fusionar, y d) un agente estabilizante que comprende un agente estabilizante con al menos un grupo funcional tiol, o sus mezclas. También se describen procedimientos para preparar el componente, su uso en medicina, en particular en la prevención de infecciones de malaria, composiciones/vacunas que contienen el componente y su uso, en particular en terapia.
DO2010000189A 2007-12-21 2010-06-18 Vacunas contra la malaria DOP2010000189A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1576207P 2007-12-21 2007-12-21

Publications (1)

Publication Number Publication Date
DOP2010000189A true DOP2010000189A (es) 2010-08-15

Family

ID=40584700

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000189A DOP2010000189A (es) 2007-12-21 2010-06-18 Vacunas contra la malaria

Country Status (22)

Country Link
US (1) US20100272745A1 (es)
EP (1) EP2234637A2 (es)
JP (1) JP2011507816A (es)
KR (1) KR20100109556A (es)
CN (1) CN102026657A (es)
AP (1) AP2010005296A0 (es)
AR (1) AR071741A1 (es)
AU (1) AU2008339980A1 (es)
BR (1) BRPI0822098A2 (es)
CA (1) CA2708716A1 (es)
CL (1) CL2008003808A1 (es)
CO (1) CO6300963A2 (es)
CR (1) CR11577A (es)
DO (1) DOP2010000189A (es)
IL (1) IL206308A0 (es)
MA (1) MA32030B1 (es)
MX (1) MX2010006984A (es)
PE (1) PE20091528A1 (es)
TW (1) TW200940086A (es)
UY (1) UY31569A1 (es)
WO (1) WO2009080715A2 (es)
ZA (1) ZA201004304B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013142278A1 (en) * 2012-03-22 2013-09-26 New York University Plasmodium vivax vaccine compositions
WO2016184784A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides including binding domain of plasmodium falciparum proteins (cbp1 and cbp2) to chemokine cx3cl1
SG11201803594TA (en) 2015-11-06 2018-05-30 Adjuvance Technologies Inc Triterpene saponin analogues
CN105233296B (zh) * 2015-11-24 2018-08-17 江苏省农业科学院 用于鸭病毒性肝炎活疫苗的耐热冻干保护剂及其制备方法和应用
GB201608821D0 (en) 2016-05-19 2016-07-06 Isis Innovation Vaccines
WO2018200656A1 (en) * 2017-04-25 2018-11-01 Adjuvance Technologies, Inc. Triterpene saponin analogues
WO2018200645A1 (en) * 2017-04-25 2018-11-01 Adjuvance Technologies, Inc. Triterpene saponin analogues
JP2020536946A (ja) 2017-10-16 2020-12-17 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物
US20220177558A1 (en) 2019-03-25 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819209D0 (en) * 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
CA2075521C (en) * 1992-05-05 1995-11-28 Kuniaki Koyama Stabilized live vaccine
ZA973642B (en) * 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
ES2234018T3 (es) * 1996-04-26 2005-06-16 MERCK & CO., INC. Formulaciones de vacunas de adn.
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
ES2298316T3 (es) * 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
CA2375829A1 (en) * 1999-06-02 2000-12-07 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
MXPA06005639A (es) * 2003-11-21 2006-08-17 Pfizer Prod Inc Adyuvante antimicrobiano.
SG149892A1 (en) * 2004-02-02 2009-02-27 Tanox Inc Identification of novel ige epitopes
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
CN101432016A (zh) * 2005-12-15 2009-05-13 Aeras全球Tb疫苗基金会 减毒的分枝杆菌的新引发-加强组合
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions

Also Published As

Publication number Publication date
IL206308A0 (en) 2010-12-30
WO2009080715A2 (en) 2009-07-02
WO2009080715A3 (en) 2009-11-12
AU2008339980A1 (en) 2009-07-02
MX2010006984A (es) 2010-10-25
AR071741A1 (es) 2010-07-14
JP2011507816A (ja) 2011-03-10
ZA201004304B (en) 2012-11-28
CA2708716A1 (en) 2009-07-02
KR20100109556A (ko) 2010-10-08
TW200940086A (en) 2009-10-01
CL2008003808A1 (es) 2011-03-11
CN102026657A (zh) 2011-04-20
PE20091528A1 (es) 2009-10-29
US20100272745A1 (en) 2010-10-28
EP2234637A2 (en) 2010-10-06
BRPI0822098A2 (pt) 2015-06-30
CO6300963A2 (es) 2011-07-21
UY31569A1 (es) 2009-08-03
CR11577A (es) 2010-09-03
MA32030B1 (fr) 2011-01-03
AP2010005296A0 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
DOP2010000189A (es) Vacunas contra la malaria
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
EA201071087A1 (ru) Моноклональные антитела, способные взаимодействовать с множеством подтипов вируса гриппа а
BR112018004242A2 (pt) composições de vacina que possuem estabilidade e imunogenicidade aumentadas
BR112018009032A2 (pt) vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração
BR112018017307A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
WO2009072767A3 (en) A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant
AR052625A1 (es) Nueva composicion
CO6260103A2 (es) Composiciones que comprenden antigenos neumococidos
BR112014024612A2 (pt) ácido nucleico, polipeptídeo, glicoproteína e quimérica, epítopo de vírus da dengue, partícula semelhante a flavivírus quimérico (vlp), flavivírus quimérico, e métodos in vitro para identificar um anticorpo neutralizante e para identificar uma composição imunogênica contra um vírus da dengue
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
AR080111A1 (es) Metodos y composiciones de inmunizacion
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
WO2013104995A3 (en) Compositions and methods for treating viral infections
MX2021015972A (es) Vacuna contra la fiebre aftosa.
WO2011151723A3 (en) Concentration of influenza vaccine antigens without lyophilization
BR112022015313A2 (pt) Vacina de hpv
BR112015031226A2 (pt) Composição de vacina, e, uso da composição de vacina
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
CL2023001846A1 (es) Parapoxvirus modificado que tiene inmunogenicidad incrementada